[go: up one dir, main page]

MX2017004440A - Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. - Google Patents

Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.

Info

Publication number
MX2017004440A
MX2017004440A MX2017004440A MX2017004440A MX2017004440A MX 2017004440 A MX2017004440 A MX 2017004440A MX 2017004440 A MX2017004440 A MX 2017004440A MX 2017004440 A MX2017004440 A MX 2017004440A MX 2017004440 A MX2017004440 A MX 2017004440A
Authority
MX
Mexico
Prior art keywords
treatment
inhalable
pulmonary hypertension
rapamycin formulation
rapamycin
Prior art date
Application number
MX2017004440A
Other languages
English (en)
Inventor
Lichenstein Henri
ARMER Thomas
M Rothberg Jonathan
S Jr Melvin Lawrence
Original Assignee
Lam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lam Therapeutics Inc filed Critical Lam Therapeutics Inc
Publication of MX2017004440A publication Critical patent/MX2017004440A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con métodos y composiciones para el tratamiento y profilaxis de hipertensión arterial pulmonar (AHP) en un sujeto humano que necesite tal tratamiento, los métodos que comprenden la administración pulmonar al sujeto, de preferencia por inhalación de una composición que comprende rapamicina o un profármaco o derivado del mismo.
MX2017004440A 2014-10-07 2015-10-07 Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. MX2017004440A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060988P 2014-10-07 2014-10-07
US201562144145P 2015-04-07 2015-04-07
PCT/US2015/054550 WO2016057712A1 (en) 2014-10-07 2015-10-07 An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Publications (1)

Publication Number Publication Date
MX2017004440A true MX2017004440A (es) 2017-11-01

Family

ID=54360545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004440A MX2017004440A (es) 2014-10-07 2015-10-07 Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.

Country Status (12)

Country Link
US (3) US20170304276A1 (es)
EP (1) EP3209330B1 (es)
JP (1) JP6679584B2 (es)
KR (1) KR20170095807A (es)
CN (1) CN107249576A (es)
AU (1) AU2015330905B2 (es)
BR (1) BR112017006842A2 (es)
CA (1) CA2963085C (es)
IL (1) IL251385B (es)
MX (1) MX2017004440A (es)
RU (1) RU2732908C2 (es)
WO (1) WO2016057712A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
CA2944075C (en) 2014-04-04 2022-06-28 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
HUE058320T2 (hu) * 2017-12-29 2022-07-28 Celon Pharma Sa Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén
CA3094453A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
EP3810091A4 (en) * 2018-05-22 2022-03-02 Abraxis BioScience, LLC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION
CA3133988A1 (en) * 2019-03-19 2020-09-24 Abraxis Bioscience, Llc Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases
BR112021021775A2 (pt) 2019-04-29 2022-01-04 Insmed Inc Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2517482A (en) 1949-04-09 1950-08-01 Sharp & Dohme Inc Inhaler
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE3345722A1 (de) 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim Inhalator
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
AU688782B2 (en) 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
CA2199954A1 (en) 1994-09-29 1996-04-04 Andrew Derek Sutton Spray-dried microparticles as therapeutic vehicles
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
DE19523516C1 (de) * 1995-06-30 1996-10-31 Asta Medica Ag Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US20040039047A1 (en) 1998-08-11 2004-02-26 Mark Zamoyski Compositions and methods for treating lung cancers
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
CA2457148A1 (en) 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
EP1424889A4 (en) 2001-08-20 2008-04-02 Transave Inc PROCESS FOR TREATING LUNG CANCERS
EP1506032A1 (en) 2002-05-20 2005-02-16 Research Development Foundation Aerosol drug inhibition of lung metastases
US20050070567A1 (en) 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
MXPA05001903A (es) * 2002-08-21 2005-04-28 Norton Healthcare Ltd Composicion para inhalacion.
ES2685436T3 (es) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
AR043504A1 (es) 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
EP1809247A1 (en) 2004-09-29 2007-07-25 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
FR2882366B1 (fr) 2005-02-18 2008-04-18 Coletica Sa Polymere reticule de carbohydrate, notamment a base de polysaccharides et/ou de polyols
MX2007010716A (es) 2005-03-02 2008-01-16 Wyeth Corp Purificacion de rapamicina.
CN101137365A (zh) * 2005-03-08 2008-03-05 生命周期药物公司 包含西罗莫司和/或其类似物的药物组合物
CA2601312A1 (en) 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
CN1883474A (zh) 2005-06-22 2006-12-27 华北制药集团新药研究开发有限责任公司 一种含大环内酯类化合物和多孔水不溶性亲水性载体的组合物
US7446096B2 (en) 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
CN101340901A (zh) 2005-12-20 2009-01-07 惠氏公司 通过控制药物物质杂质控制cci-779剂型稳定性
GB0602123D0 (en) 2006-02-02 2006-03-15 Novartis Ag Organic compounds
PL1983984T3 (pl) 2006-02-02 2018-08-31 Novartis Ag Leczenie stwardnienia guzowatego
US20100081681A1 (en) 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
EP2079748A4 (en) 2006-11-10 2011-05-04 Biocon Ltd PURE FORM OF RAPAMYCIN AND ITS RECOVERY AND PURIFICATION PROCESS
EP2092942A1 (en) 2006-11-20 2009-08-26 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080138405A1 (en) 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
EP1952807A1 (en) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
US9370508B2 (en) 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
EP2146707A2 (en) 2007-05-03 2010-01-27 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
CA2723314C (en) 2008-02-13 2017-01-10 The Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
CN102292078A (zh) * 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
CN102292072A (zh) 2009-01-26 2011-12-21 特瓦制药工业有限公司 用微粒包衣载体的方法
US20100196483A1 (en) 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
GB0905818D0 (en) 2009-04-06 2009-05-20 Airbus Uk Ltd Coupling assembly
US8492110B2 (en) 2009-04-10 2013-07-23 Haiyan Qi Anti aging agents and methods to identify them
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
US9248110B2 (en) * 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
PT105058B (pt) * 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
WO2011163600A2 (en) 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
US20140037548A1 (en) * 2010-06-28 2014-02-06 The Board Of Trustees Of The Leland Standford Junior University Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
EP2621588A4 (en) 2010-09-27 2014-09-03 Microdose Therapeutx Inc METHODS AND COMPOSITIONS FOR TREATING DISEASE USING INHALATION
CN102670518B (zh) * 2011-03-14 2014-08-20 齐鲁制药有限公司 一种难溶性药物球形颗粒的制备方法
US20140067548A1 (en) 2012-08-31 2014-03-06 Sap Ag Saving on device functionality for business calendar
EP3721784B1 (en) 2013-03-28 2023-12-20 EndoChoice, Inc. Compact multi-viewing element endoscope system
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
US20150265582A1 (en) 2014-02-11 2015-09-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CA2944075C (en) 2014-04-04 2022-06-28 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
DE102014005466A1 (de) 2014-04-12 2015-10-15 Klaus Düring Verfahren zur Gewinnung von Napin und Cruciferin oder einem Gemisch davon aus Raps
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) * 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN108039392A (zh) 2017-11-06 2018-05-15 北京汉能薄膜发电技术有限公司 铜铟镓硒化合物、油墨及其薄膜吸收层制备方法

Also Published As

Publication number Publication date
WO2016057712A1 (en) 2016-04-14
RU2017115990A (ru) 2018-11-13
US11491143B2 (en) 2022-11-08
IL251385A0 (en) 2017-05-29
US20230255944A1 (en) 2023-08-17
US20200306230A1 (en) 2020-10-01
NZ731059A (en) 2023-12-22
EP3209330B1 (en) 2022-02-23
CN107249576A (zh) 2017-10-13
JP6679584B2 (ja) 2020-04-15
AU2015330905B2 (en) 2021-02-25
BR112017006842A2 (pt) 2017-12-12
CA2963085C (en) 2023-02-21
JP2017534604A (ja) 2017-11-24
EP3209330A1 (en) 2017-08-30
RU2732908C2 (ru) 2020-09-24
US20170304276A1 (en) 2017-10-26
KR20170095807A (ko) 2017-08-23
CA2963085A1 (en) 2016-04-14
RU2017115990A3 (es) 2019-05-08
IL251385B (en) 2022-05-01
AU2015330905A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
MX2017004440A (es) Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
MX2016010373A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
ZA201606320B (en) Human plasma kallikrein inhibitors
PL3307289T3 (pl) Sposoby wytwarzania kompozycji do terapii przywracającej mikrobiotę (mrt)
MX2016013486A (es) Activadores de canales ionicos y metodos de uso.
MX381173B (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
EA201692422A1 (ru) Состав, содержащий пролекарство гемцитабина
PH12018500544A1 (en) Inhalable nicotine formulations, and methods of making and using thereof
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
IN2013MU03583A (es)
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
EA036036B1 (ru) Композиции, содержащие циклоспорин
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
MX2017014301A (es) Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
TW201613563A (en) Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof
IN2014DE00822A (es)